An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo
about
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T CellsGenetically modified T cells in cancer therapy: opportunities and challengesAntibody humanization by structure-based computational protein design.Strategies to genetically engineer T cells for cancer immunotherapy.Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor ImmunityB7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsThe role of B7 family molecules in hematologic malignancyImmunotherapy in pediatric malignancies: current status and future perspectivesGroup 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production.B7 family checkpoint regulators in immune regulation and disease.Adoptive immunotherapy for cancer.Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen ReceptorsCombination cancer immunotherapies tailored to the tumour microenvironment.Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.Engineering Chimeric Antigen Receptors.New B7 Family Checkpoints in Human Cancers.Termination of the Activating NK Cell Immunological Synapse Is an Active and Regulated Process.Practical considerations for chimeric antigen receptor design and delivery.Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.The B7 Family Member B7-H6: a New Bane of Tumor.The prognostic value of B7-H6 protein expression in human oral squamous cell carcinoma.T-bet promotes potent antitumor activity of CD4+ CAR T cells.T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology.Construction of a human monoclonal antibody against bFGF for suppression of NSCLC.
P2860
Q27026484-892B8C56-DD61-4CF1-B6E8-2CECA58E19A6Q27026627-C1107EA6-5536-407E-925B-818566AA5622Q30377654-FE817F89-4771-4ABF-BE79-A0DF7A65A603Q33655849-87CDEC8A-3B63-4773-962F-15EA1BA5A181Q34256494-A2312ECD-D9BA-49F8-A59C-49A96BC301B6Q34786615-F3F53FBF-D4A7-49FE-9F00-CAF5773ECCBBQ35209066-6C352DFD-C204-4B8D-AE14-8E923B02C82DQ35613233-7583E0ED-445A-497E-B3D7-8298D0253F22Q35929030-E1F17299-6E66-49F2-BA37-67C657D3E0D2Q36470354-A0E68203-8723-4290-9F47-E3C85DFDDDD4Q36584814-125B7E81-FEF2-4C0B-9960-BF86F0E9FF21Q36691818-DA2FC5DC-6918-42C3-B868-108C013FBC13Q37021079-35B839C8-DC03-4894-9ED5-FFA8ED5838D0Q38129635-6E19D641-646F-4AD2-8E79-C4BF52928329Q38170496-A3E0B015-BF43-47AD-8559-A1CBD6FBB1A4Q38170500-66ADE01B-81BD-4AAB-8F06-FA1B919CE6A5Q38603686-A68BACAB-F98D-44FA-A3DE-04C5EC05A936Q38645178-E481C8AC-F071-4B89-99AF-28FAA058C626Q38730881-7D798D31-C9D7-42B8-8DB5-3EF152B99AD9Q38770555-5DD263C2-4A86-4511-924A-08E7DE188C94Q38830813-94E92C84-E69A-4B8D-8397-DB73B364A0F6Q39276909-0F395B38-B518-4214-849A-C9CA28161861Q39416195-1E617BE4-6F7F-4126-BE4C-112977B7C877Q40073065-048E6A4B-7E98-4A0B-91F7-8D4ED690378FQ45868559-26850A8C-5A2B-4806-9935-ECBE21DDAD58Q47111488-8CAC95BF-7432-4D0A-89D8-A5DE5068798BQ47193084-7A65B7BA-85E9-4B64-B7F4-701DBC6C4414Q47436657-7DE785C3-82AD-4E3E-9EB1-D1AD2DE6AEA1Q48098708-CD57D7A2-07B0-416F-AC73-D37CAC6C772CQ48239951-0779AE81-7D48-4C59-AA72-5F5BBC257F9BQ52668512-A9E59484-5CBC-4333-BC8D-4EA7BE59F820Q52689465-A80E3C3A-DFD5-4A71-A709-6309EB2F1E62Q55473120-B95BCA70-408B-4E36-B975-D359641C9DE9
P2860
An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
An NKp30-based chimeric antige ...... and antitumor efficacy in vivo
@en
type
label
An NKp30-based chimeric antige ...... and antitumor efficacy in vivo
@en
prefLabel
An NKp30-based chimeric antige ...... and antitumor efficacy in vivo
@en
P2860
P356
P1476
An NKp30-based chimeric antige ...... and antitumor efficacy in vivo
@en
P2093
Charles L Sentman
Ming-Ru Wu
P2860
P304
P356
10.4049/JIMMUNOL.1103495
P407
P50
P577
2012-07-30T00:00:00Z